OSL · TRMED.OL
Thor Medical ASA
NOK 4.15-NOK 0.07 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
Loading market information…
OSL · LYTIX.OL · NOK
Stock price, earnings
Quote as of Oct 29, 2026, 02:37 PM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lytix Biopharma AS’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lytix Biopharma AS’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 4.15-NOK 0.07 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
NOK 3.08+NOK 0.06 (+1.82%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.25% below the high.
NOK 38.60NOK 0.00 (0.0%)
Gentian Diagnostics AS’s quoted price sits in the lower half of its reported 52-week range, 35.67% below the high.
NOK 1.30NOK 0.00 (0.0%)
Hofseth BioCare ASA’s quoted price sits in the lower half of its reported 52-week range, 37.14% below the high.
NOK 4.37-NOK 0.13 (-2.89%)
ContextVision AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 24.39% below the high.
NOK 11.25+NOK 0.25 (+2.27%)
Navamedic ASA’s quoted price sits in the lower half of its reported 52-week range, 57.55% below the high.
NOK 0.44+NOK 0.01 (+2.69%)
Lifecare AS’s quoted price sits in the lower half of its reported 52-week range, 92.81% below the high.
NOK 2.28+NOK 0.08 (+3.64%)
Arctic Bioscience AS’s quoted price sits in the lower half of its reported 52-week range, 45.71% below the high.
